Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.
about
Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK CellsTrial Watch: Adoptive cell transfer for oncological indicationsImmune reconstitution in chronic lymphocytic leukemiaSelective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptorAdvantages and applications of CAR-expressing natural killer cellsUtilizing chimeric antigen receptors to direct natural killer cell activityChimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor ImmunityRedirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspectiveGenetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigensGenetic redirection of T cells for cancer therapy.Natural killer cell lines in tumor immunotherapy.NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.In Vitro Generation of Human NK Cells Expressing Chimeric Antigen Receptor Through Differentiation of Gene-Modified Hematopoietic Stem Cells.CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.Adoptive Cellular Therapy (ACT) for Cancer Treatment.Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.Markers and function of human NK cells in normal and pathological conditions.Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy.Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor.Engineering Natural Killer Cells for Cancer Immunotherapy.Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Are natural killer cells superior CAR drivers?Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.Practical considerations for chimeric antigen receptor design and delivery.Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma.Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells.NK-92 cell, another ideal carrier for chimeric antigen receptor.Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.Versatile CAR T-cells for cancer immunotherapy.Microfluidic generation of transient cell volume exchange for convectively driven intracellular delivery of large macromolecules
P2860
Q26751020-7636516B-D4CB-45D4-B891-4BAE4DBCE7EAQ26785545-62DBCF72-B102-4C3C-B2DD-56F5C834249CQ26865561-590950EF-894F-441B-8093-F0E352E3B41BQ27318470-165F850A-A828-433E-AC07-F7843D3C848BQ28080875-9EBD82D3-A419-4FFF-8A65-F07563118F51Q28082868-9A84B6B5-6661-4FEE-A1E7-3F059FA901C8Q33700795-A563196F-52CF-4F7F-8496-72A47D10B3B3Q34122292-82E4E364-C47C-478E-9299-FD829DF55454Q34180695-AB5BC7AA-0E16-4C06-99D5-2E1CCD4CE2BEQ35711209-F8139BD2-CE81-4E60-874C-D7FF7AFF03ADQ36377047-61EE2FA2-1C6D-4CED-84F1-298623889107Q37697337-15B061D8-1C9F-4076-B5BD-4EE9A55463D1Q37998371-CDDD6358-B007-4949-A1C2-0BC1E4646FA6Q38631020-88FAA34D-BA3E-4EF6-8962-F9E85EB526D4Q38722015-14E23201-1A05-4182-B4C6-93AC534DA242Q38753649-424243BB-7739-459C-8FA5-A9E1F6BB4DE0Q38771094-35B81B85-0E51-4998-95BD-5510A3AEAFCEQ38783833-00819028-EE83-46F1-9897-6B8B5C8FD882Q38848219-77FC20DD-4A93-48C4-9F89-824C2C5C8A2CQ39037600-83A79302-3296-4714-A990-9E889A8645BFQ39068084-5DE9ECF5-2146-4D12-BF6F-2A3FBC5B3F35Q39317127-FFA690F5-7684-475A-B641-20D8BDCEA74FQ39400633-F7D2CD21-877E-4520-A7C9-26E00566061AQ39408704-5B216F4D-ABB6-43DA-9546-6F1E562BF9A1Q39718346-D3CDBA56-8A45-4C45-914D-C19A0CDF573BQ42702234-72103DBD-5C0E-4273-9ED8-69D3BA9BEE2EQ42952399-75AC31F3-98E1-4323-951A-5AE7BE60A54FQ45009828-C64232E2-6C24-4D9E-AB42-D376066A4FD6Q45868559-84051C23-4B3A-4178-A505-F0181C890113Q46366459-CE491AD2-7454-4EEB-BD21-0A950CF1B46EQ48504970-51F67F24-FCCC-4D83-8DE0-EBFB65C80EFFQ49290997-C0CAF14A-2A04-4433-BC92-161373CE4751Q50027824-DF5B407A-2AB5-47C7-B0D4-BDA9F41B2F4BQ53705286-0ADD76FD-24F0-457A-9E1B-A8EFC364C72BQ55347731-34EF86C0-2A83-465E-AA4E-E4FF85E2B3EDQ57127092-65C2C22E-93EC-4C98-B37B-105A101AFE64
P2860
Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Transfection with mRNA for CD1 ...... mediated killing of CLL cells.
@en
Transfection with mRNA for CD1 ...... mediated killing of CLL cells.
@nl
type
label
Transfection with mRNA for CD1 ...... mediated killing of CLL cells.
@en
Transfection with mRNA for CD1 ...... mediated killing of CLL cells.
@nl
prefLabel
Transfection with mRNA for CD1 ...... mediated killing of CLL cells.
@en
Transfection with mRNA for CD1 ...... mediated killing of CLL cells.
@nl
P2093
P2860
P1433
P1476
Transfection with mRNA for CD1 ...... mediated killing of CLL cells.
@en
P2093
Hande Tuncer
Hans Klingemann
Laurent Boissel
Monica Betancur
Winfried S Wels
P2860
P304
P356
10.1016/J.LEUKRES.2008.11.024
P577
2009-01-14T00:00:00Z